Could the Hurricane Energy share price be the bargain of the year?

G A Chester weighs up the potential of exciting oil stock Hurricane Energy plc (LON:HUR) and a pharma firm aiming to rise like a phoenix.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There’s no shortage of loss-making-but-high-potential companies on the stock market. Oil explorers and developers and pharmaceuticals and medical technology firms offer the prospect of particularly big gains for investors who identify the right company at the right price.

Of course, this is easier said than done. For every millionaire-maker there are dozens of duds. Today, I’m weighing up the potential of oil stock Hurricane Energy (LSE: HUR) and pharma player Circassia (LSE: CIR), which released its annual results today.

Collapse

Heavily backed by cornerstone investors Neil Woodford and his protégé at former employer Invesco, Circassia pursued the development of a whole platform of allergy treatments that were said to build immunity quicker than existing remedies and without the risk of anaphylactic shocks. When its lead cat allergy failed a Phase III study, the entire programme collapsed.

At the height of investor confidence, Circassia was a member of the FTSE 250 index, with a share price of 350p and market capitalisation of over £1bn. Today, it’s on the AIM market, its share price is 31.5p (down a little on the back of its results) and its market cap is £118m. Its accounts show an accumulated loss of over half-a-billion quid.

However, it now has a small portfolio of revenue-generating products, including via a commercial collaboration with AstraZeneca, which has also become a 19% shareholder in Circassia. Could the stock be set to rise like a phoenix?

Recovery?

Just over a year ago, I wrote that I wouldn’t touch Circassia with a bargepole, noting also a 5.42% short position in the stock held by hedge fund Mangrove.

Today’s results showed a £37.2m operating loss on revenue of £48.3m. There are signs of promising revenue growth, and with the share price much lower than a year ago, the valuation picture has improved.

However, continued losses are forecast into next decade and Mangrove has maintained its chunky short position. I’m not convinced the risk/reward proposition with Circassia is compelling, and so continue to see it as a stock to avoid at this stage.

Share price to double?

By contrast, when I last wrote about Hurricane Energy (November 2017), I felt its progress to date, potential to become a major player in the West of Shetland region, and share price of 26.75p (market cap £524m) represented an attractive risk/reward proposition. The shares are currently trading at around 47p (market cap £921m), but I continue to see a compelling investment opportunity.

The company is on track to deliver first oil from its 100%-owned Lancaster discovery before the end of June. Planned initial production is 17,000 barrels a day, and management expects to generate over $200m in operating cash flow on a full-year run-rate basis at a $60 a barrel Brent oil price.

Meanwhile, a 50% farm-in to its Warwick and Lincoln fields by Spirit Energy, providing up to $387m, has enabled an acceleration of activity, including the drilling of three wells this year, one of which was spudded last month.

If we see the company successfully executing on this year’s work programme, I think the share price could easily double from its current level. And with total 2P reserves and 2C contingent resources across the asset base standing at 2.3bn barrels net to Hurricane, there’s potential for the value of the company to continue increasing as time goes on.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black woman using smartphone at home, watching stock charts.
Investing Articles

Tesla stock just got a little cheaper, but why? And should anyone care?

Tesla stock's phenomenally expensive, but that hasn't stopped retail investors from piling in over the past year. Dr James Fox…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

I’m targeting an £8,299 annual income from £20,000 in this transformed FTSE energy star!

This FTSE energy firm has transformed since 2024, creating a deeply undervalued and high-yielding proposition that many investors overlook, in…

Read more »

Cropped shot of an affectionate young couple posing with a bunch of flowers in their kitchen on their anniversary
Investing Articles

Love bargains? 4 stock market gems to consider this new ISA year

Searching for top quality stocks at rock-bottom prices? Royston Wild reveals four stock market value heroes to consider in an…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

6.3% passive income yield! A brilliant, bargain-basement dividend stock to buy?

Searching for the best dividend stocks to buy as the new ISA year begins? Royston Wild reveals a rock-solid passive…

Read more »

Investing Articles

Can nothing stop the rampant HSBC share price?

Harvey Jones is blown away by the HSBC share price, which still looks great value despite recent brilliant performance. Are…

Read more »

Landlady greets regular at real ale pub
Investing Articles

5.5%+ yields! 3 REITs to target a £1,300 passive income in an ISA

Looking for ways to boost passive income? All these real estate investment trusts (REITs) carry huge dividend yields, including one…

Read more »

Young black woman using a mobile phone in a transport facility
Investing Articles

£5,000 buys 709 shares in this 8.1%-yielding passive income stock!

Looking for ways to make a large passive income with UK dividend stocks? Royston Wild discusses a high-yielder with excellent…

Read more »

Finger clicking a button marked 'Buy' on a keyboard
Investing Articles

47% under ‘fair’ value, with 9% annual forecast earnings growth! 1 FTSE 100 gem to buy today?

This FTSE 100 financial giant is 18% off its highs. With profits surging and returns climbing, could the market be…

Read more »